Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11445050 | 0.79 | IDO1 (0.52) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL1444030 | 0.79 | IDO1 (0.52) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL28443686 | 0.79 | IDO1 (0.52) | KDM4EIDO1HTR2AMAOBPAM | |
| Hydrochloric Acid SCHEMBL5694867 | 0.78 | IDO1 (0.53) | KDM4EIDO1HTR2AMAOBPAM | |
| Hydrochloric Acid SCHEMBL11531572 | 0.78 | IDO1 (0.53) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL2770961 | 0.74 | KDM4E (0.55) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL2770965 | 0.74 | KDM4E (0.55) | KDM4EIDO1HTR2AMAOBPAM | |
| Hydrochloric Acid SCHEMBL11524700 | 0.74 | RAB9A (0.47) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL18025762 | 0.73 | MAOB (0.58) | KDM4EIDO1HTR2AMAOBPAM | |
| SCHEMBL4073166 | 0.73 | MAOB (0.58) | KDM4EIDO1HTR2AMAOBPAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160223559-A1 | TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160223559-A1 | TETRAZINE-CONTAINING COMPOUNDS AND SYNTHETIC METHODS THEREOF | HCK, TTK, TLK1 | KDM4E 2631/4885IDO1 1222/4885HTR2A 1640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.